全 文 ：
Journal of Chinese Pharmaceutical Sciences http://www.jcps.ac.cn 421
Anomalusins A and B, two new ent-rosane diterpenoids from Mallotus
anomalus
Gang Ni, Shengping Yang, Jianmin Yue*
State Key Laboratory of Drug Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai 201203,
China
Abstract: Two new ent-rosane type diterpenoids, anomalusins A (1) and B (2), together with ten known compounds were
isolated from the plants of Mallotus anomalus Meer et Chun. The structures of compounds 1 and 2 were fully elucidated on the
basis of spectroscopic evidence, and CD analysis.
Keywords: Mallotus anomalus; Diterpenoid; Absolute configuration
CLC number: R284.1 Document code: A Article ID: 1003–1057(2012)5–421–07
Received date: 2012-05-12.
*Corresponding author. Tel./Fax: 86-21-50806718;
E-mail: jmyue@mail.shcnc.ac.cn
Dedicated to Professor Lihe Zhang on the occasion of his 75th birthday.
doi:10.5246/jcps.2012.05.056
1. Introduction
The genus Mallotus (Euphorbiaceae) comprising
of 150 species mainly grows in tropical regions of
the Northern Hemisphere[1]. There are about 40 species
of this genus in China, among which some have been
used in folk medicine for the treatment of chronic
hepatitis, cholecystitis and gastrointestinal disorders[2,3].
The extracts and/or the components of Mallotus
plants have been reported to have hepatoprotective,
anti-inflammatory, antiviral, antimicrobial, antioxi-
dant, anti-HIV, and cytotoxic activities[3,4]. Mallotus
anomalus Meer et Chun is an evergreen shrub only
distributed in the mountain areas of Hainan Island
of China. The isolation of cytotoxic diterpenoids from
this plant were reported previously[5–7]. In the present
study, two new compounds, anomalusins A (1) and
B (2), as well as 10 known isolates were isolated
from M. anomalus. We present herein the isolation
and structural elucidation of these compounds.
2. Experimental
2.1. General experimental procedures
Optical rotations were recorded on a Perkin-Elmer




341 polarimeter. IR spectra were recorded on a
Perkin-Elmer 577 spectrophotometer. NMR spectra
were obtained on a Bruker AM-400 spectrometer.
HRESIMS data were recorded on a Waters-LCT
Premier XE spectrometer. Silica gel (300–400 mesh,
Qingdao Marine Chemical Factory), Sephadex LH-20
(Pharmacia Biotech, Sweden), MCI gel (CHP20P,
75–150 mm, Mitsubishi Chemical Industries Ltd.),
and ODS (40–60 mm, Merck) were used for column
chromatography. TLC was performed on GF254 plates
(Qingdao Marine Chemical Factory) or TLC plates
precoated with PR-18 GF254 (Merck). HPLC was
carried out using a Waters 1525 Binary HPLC pump
equipped with a Waters UV/Visible Detector and
YMC-Pack ODS-A column (10 mm×250 mm, 5 mm).
2.2. Plant material
The plant material of Mallotus anomalus Meer et
Chun was collected from Hainan province, China. A
voucher specimen has been deposited at Shanghai
Institute of Materia Medica (Accession number:
MA-2010-1Y).
2.3. Extraction and isolation
The air-dried powder of the roots of Mallotus
anomalus (10 kg) was extracted with 95% EtOH at
room temperature for three times. The extracts
were concentrated under vacuum to give a residue
(300 g), which was suspended in water and extracted

with petroleum ether, ethyl acetate, and BuOH
successively. The EtOAc-soluble fraction (65 g) was
chromatographed on an MCI-gel column (MeOH–H2O,
0–100%, v/v) to give five fractions 1–5. Fraction 2
(3 g) was chromatographed over a silica gel column,
eluted with petroleum ether–EtOAc, to afford six
fractions, 2a–2g. Fraction 2a (90 mg) was purified
on a Sephadex LH-20 column (MeOH) to give
compound 6 (6 mg). Fraction 2b (300 mg) was
fractionated by RP-18 silica gel column (MeOH–H2O,
40%–100%, v/v) to give compounds 7 (9 mg) and
8 (12 mg). Fraction 2d (600 mg) was separated on a
reversed-phase C18 silica gel column (MeOH–H2O,
40%–100%, v/v), and then was purified by silica gel
column chromatography (petroleum ether–EtOAc,
10:1–0:1, v/v) to give 9 (2.5 mg). Fraction 3 (2 g)
was subjected to silica gel column (CHCl3–MeOH,
300:1–10:1, v/v) to give five sub-fractions, 3a–3f.
Fraction 3b (550 mg) was chromatographed over a
column of reversed-phase C18 silica gel (MeOH–H2O,
50%–80%, v/v) to afford six fractions, 3b1–3b6.
Fraction 3b3 (90 mg) was separated over a silica gel
column (petroleum ether–acetone, 10:1–0:1, v/v),
followed by semi-preparative HPLC to obtain 10
(18 mg). Fraction 3b4 (200 mg) was separated
over a silica gel column (petroleum ether–acetone,
10:1–0:1, v/v), followed by the purification on a
Sephadex LH-20 column (MeOH), to give 11 (8 mg).
Fraction 3c (350 mg) was separated on a silica gel
column (petroleum ether–acetone, 10:1–0:1, v/v) and
then purified by Sephadex LH-20 column (MeOH)
to afford 12 (14 mg). Fraction 4 (3 g) was subjected to
silica gel chromatography (petroleum ether–acetone,
50:1–0:1, v/v) to yield six sub-fractions 4a–4f.
Fraction 4c (0.2 g) was fractionated by RP-18 silica
gel column (MeOH–H2O, 50%–100%, v/v) to give
five fractions 4c1–4c5. Fraction 4c2 (30 mg) was
separated by Sephadex LH-20 column (MeOH)
and further by semi-preparative HPLC to obtain 1
(2 mg), 2 (3 mg), and 3 (12 mg). Fraction 4d (500 mg)
was separated on RP-18 silica gel column to afford
fractions 4d1–4d6. 4d3 (70 mg) was further purified
by semi-preparative HPLC to obtain 4 (7 mg), and
5 (6 mg).
Figure 1. Structures of compounds 1–12.
OH
O
HO
OH
O1
2
3 4
5
6
7
8
9
10
11 12
13
14
15
16
17
18 19
20
1 2 3 4
HO
H HH H
HO
H
OH
O
OH
H
OH
O
OH
HO
O
H
OHOH
5 6 7
O
O
HO
OH
O
OOH
HO
O OH
OH
8 9 10
O OH
OH
O
OH
OMe
11 12
O
OH
HO
HO
OH
422 G. Ni et al. / Journal of Chinese Pharmaceutical Sciences 21 (2012) 421–427

423 G. Ni et al. / Journal of Chinese Pharmaceutical Sciences 21 (2012) 421–427
3. Structural identification
3.1. Anomalusin A (1)
Compound 1, obtained as a white solid, was
assigned the molecular formula C20H30O3 from
HRESIMS (m/z 659.4288 [2M+Na]+), which was
consistent with six degrees of unsaturation. Its
optical value was –76 (c 0.095, MeOH). The IR
spectrum showed the presence of hydroxy (3437 cm–1)
and a carbonyl (1716 cm–1) groups. Analysis of the
1H NMR spectrum for 1 (Table 1) revealed reso-
nances for a terminal double bond [δH 5.94 (1H, dd,
J1 10.8 Hz, J2 17.6 Hz, H-15); 4.99 (1H, dd, J1 0.8 Hz,
J2 10.8 Hz, H-16); 5.04 (1H, dd, J1 0.8 Hz, J2 17.6 Hz,
H-16)], a trisubstituted double bond [δH 5.84 (1H,
m, H-6)], as well as four isolated singlet methyls at
δH 0.87 (3H, s, H-20), 1.26 (3H, s, H-19), 1.01 (3H,
s, H-17) and 0.85 (3H, s, H-18). In addition, the
presence of two proton signals at δH 3.58 (1H, dd,
J1 4.4 Hz, J2 12.0 Hz, H-12) and 3.96 (1H, s, H-3)
assignable to the oxygenated methines were also
observed in the 1H NMR spectrum (Table 1). All 20
carbons in the molecule of 1 were resolved in the
13C NMR spectrum (Table 1), and categorized by
DEPT and HSQC experiments as one carbonyl (δC
212.8), four methyls, five methylenes (one olefinic),
six methines (two olefinic, two oxygenated), and
four quaternary carbons (one olefinic). Two double
bonds and one carbonyl group accounted for three
degrees of unsaturation, the remaining ones required
that compound 1 being tricyclic. Analysis of the
1H-1H COSY of 1 enabled us to distinguish four
isolated spin systems (C-1–C-10, C-6–C-7–C-8–C-14,
C-11 to C-12, and C-15 to C-16). These subunits
and non-protonated carbons were connected to each
other on the basis of HMBC correlations (Fig. 2).
The HMBC correlations from H-1 to C-2 (δC 212.8)
and C-3 (δC 81.6), from H-3 to C-2, from H-10 to
C-4, and C-5, and from H3-18 and H3-19 to C-3,
C-4, and C-5 allowed to furnish the A-ring, and to
place a keto group and a hydroxyl at C-2 and C-3
respectively. The mutual HMBC correlations of
H-10/C-5, C-6 and C-9; H3-20/C-8, C-9 and C-11;
H-7/C-5, C-6 and C-8; H3-17/C-12 (δC 73.2), C-13,
and C-14; H-15 and H-16/C-13; and H-8/C-7 and































C-14 enabled us to construct the B and C-rings, and
locate a hydroxyl group at C-12. On the basis of the
above analysis, compound 1 was established as a
tricyclic ent-rosane type diterpenoid.
The relative stereochemistry of 1 was established
on the basis of ROESY experiment (Fig. 3). The
correlations of H-17/H-8, H-17/H-11β, H-10/H-11β,
and H-10/Me-18 indicated that H-8, H-10, H-17, and
Me-18 were co-facial and were arbitrarily assigned as
a β-configuration. Consequently, the ROESY cross-
peaks of H-3/Me-19, H-3/H-1α, H-12/H-15, and
Me-20/H-12 revealed that H-3, Me-20, and Me-19
were α-oriented. The absolute configuration of 1 was
determined by its CD spectrum. The positive Cotton
effect at 304 nm (Δε +0.54) due to the n→π* transition
1 2
δH mult (J in Hz) δC δH mult (J in Hz) δC
1 2.38 t (12.8)
2.48 m
39.4 2.33 dd (13.6, 18.0)
2.54 dd (5.6, 18.0)
36.5
2 212.8 213.8
3 3.96 s 81.6 4.10 s 81.1
4 47.8 42.3
5 143.0 143.4
6 5.84 m 123.0 5.78 m 121.2
7 1.90 dt (17.6, 5.2)
1.78 m
30.5 1.95 m
1.63–1.75 m
30.6
8 1.58 m 37.5 1.63–1.75 m 37.0
9 38.2 37.0
10 2.53 m 49.3 2.67 m 45.9
11 1.71 dd (4.4, 12.8)
1.32 t (12.0)
43.1 1.63–1.75 m
1.34 t (12.4)
42.9
12 3.58 dd (4.4, 12.0) 73.2 3.58 dd (4.4, 12.0) 72.9
13 43.2 43.2
14 1.39 t (12.8)
1.24 dd (12.8, 5.6)
41.0 1.23 dd (12.0, 2.8)
1.48 t (12.0)
40.6
15 5.94 dd (10.8, 17.6) 149.8 5.94 dd (11.2, 17.6) 149.4
16 4.99 dd (0.8, 10.8)
5.04 dd (0.8, 17.6)
112.5 4.99 dd (0.8, 10.8)
5.04 dd (0.8, 17.6)
111.9
17 1.01 s 16.2 1.02 s 15.7
18 0.85 s 23.3 0.90 s 24.8
19 1.26 s 24.9 1.21 s 27.5
20 0.87 s 14.3 0.79 s 12.9
No.
Table 1. 1H and 13C NMR data (δ) of compounds 1 and 2 in CD3OD
20
D[α]
Figure 2. 1H-1H COSY (▬) and selected HMBC correlations (H→C)
of anomalusin A (1).
OH
O
HO

G. Ni et al. / Journal of Chinese Pharmaceutical Sciences 21 (2012) 421–427 424
of the cyclohexanone unit suggested that the abso-
lute configuration of 1 was (3R,8S,9S,10R,12R,13S)
according to the octant rule. As shown in Figure 4,
the CD curve of 1 only showed a weak positive
ellipticity in the region of 270–330 nm due to the
reason that the equatorial 3-OH is almost coplanar
with the horizontal plane, and is expected to give a
weak contribution to the Cotton effect.





































3.2. Anomalusin B (2)
Compound 2, a white solid with the specific rota-
tion of +94 (c 0.125, MeOH), was assigned the
molecular formula of C20H30O3 as determined by
HREIMS at m/z 319.2244 [M+H]+. The IR spectrum
showed the presence of hydroxy groups (3450 cm–1)
and a carbonyl group (1716 cm–1). Analysis of the
1H and 13C NMR spectra indicated that the structure
of 2 highly resembled that of 1. A comprehensive
2D NMR analysis further revealed that compound 2
shared the same planar structure with 1. Compared
with compound 1, the C-1, C-4, and C-10 of 2
were upfield shifted by ΔδC 2.9, 5.5, and 3.4 ppm,
respectively, whereas the C-2, C-18 and C-19 of 2
were downfield moved by ΔδC +1.0, 1.5 and +2.6,
respectively, indicating that 2 is the C-3 epimer of
1, which was confirmed by ROESY spectrum
(Fig. 3). The ROESY spectrum also revealed that
the other stereogenic centers C-8, C-9, C-10, C-12,
and C-13 were same as those of 1. The absolute
configuration of 2 was also determined by its CD
spectrum. The positive Cotton effect at 287 nm
(Δε +2.47) from the n→π* transition of the cyclo-
hexanone allowed the assignment of the absolute
configuration (3S,8S,9S,10R,12R,13S) for 2 accord-
ing to the octant rule. The CD curve of 2 showed a
more stronger positive ellipticity in the region of
250–320 nm than that of 1 attributable to the contri-
bution of 3α-OH, which took the axial bond of the
chair-conformed A-ring, and landed at the first
sphere of the carbonyl group that normally causes
the strongest perturbation of the n→π* absorption.
3.3. Anomallotusinsin (3)
White solid; 1H NMR (400 MHz, CDCl3) δ: 0.69
(3H, s, H-20), 1.01 (3H, s, H-19), 1.25 (3H, s, H-18),
1.30 (1H, s, H-17), 1.90 (1H, m, H-3), 2.17 (1H,
d, J 14.0 Hz, H-11), 2.38 (1H, d, J 14.0 Hz, H-11),
3.79 (1H, dd, J1 4.8 Hz, J2 12.0 Hz, H-6), 5.03 (1H,
d, J 17.6 Hz, H-16), 5.11 (1H, d, J 10.8 Hz, H-16),
6.15 (1H, dd, J1 10.8 Hz, J2 17.6 Hz, H-6). 13C NMR
(100 MHz, CDCl3) δ: 24.3 (C-1), 19.7 (C-2), 31.9
(C-3), 42.4 (C-4), 79.0 (C-5), 72.3 (C-6), 30.3 (C-7),
42.1 (C-8), 41.1 (C-9), 49.4 (C-10), 52.5 (C-11),
214.1 (C-12), 50.8 (C-13), 40.6 (C-14), 142.8 (C-15),
Figure 3. Key ROESY correlations (↔) of anomalusins A (1) and
B (2).
20
D[α]
Figure 4. CD and UV spectra of anomalusins A (1) and B (2) and
octant projections of 1 and 2.
1 2
HO
OHO
HO
OH
O
250 300 350 400
Wavelength (nm)
1
2
C
D
[m
de
g]

H
T
[V
]
10






0
500



400



300
1
2

G. Ni et al. / Journal of Chinese Pharmaceutical Sciences 21 (2012) 421–427 425
112.6 (C-16), 23.7 (C-17), 16.0 (C-18), 14.7 (C-19),
14.5 (C-20). The 1H and 13C NMR data were in
agreement with those in literature[6], and the structure
of 3 was identified as anomallotusinsin.
3.4. Anomaluone (4)
White solid; 1H NMR (400 MHz, CDCl3) δ: 1.09
(3H, s, H-20), 1.11 (3H, s, H-18), 1.24 (3H, s, H-19),
1.38 (1H, d, J 8.4 Hz, H-9), 1.42–1.63 (8H, m),
1.77 (1H, dd, J1 6.4 Hz, J2 15.2 Hz, H-14), 2.14 (1H,
m, H-5 and H-13), 3.41 (1H, d, J 10.8 Hz, H-17), 3.49
(1H, d, J 10.8 Hz, H-17), 5.84 (1H, d, J 10.4 Hz, H-2),
7.16 (1H, d, J 10.4 Hz, H-1). 13C NMR (100 MHz,
CDCl3) δ: 160.5 (C-1), 125.6 (C-2), 205.9 (C-3),
43.8 (C-4), 53.3 (C-5), 20.6 (C-6), 41.1 (C-7), 44.8
(C-8), 50.3 (C-9), 41.5 (C-10), 19.1 (C-11), 26.6
(C-12), 40.6 (C-13), 38.7 (C-14), 52.1 (C-15), 79.6
(C-16), 70.0 (C-17), 28.4 (C-18), 21.3 (C-19), 21.4
(C-20). The 1H and 13C NMR data were in agree-
ment with those in literature[5], and the structure of 4
was identified as anomaluone.
3.5. Abbeokutone (5)
White solid; 1H NMR (400 MHz, CDCl3) δ: 1.02
(3H, s, H-19), 1.07 (3H, s, H-18), 1.08 (3H, s, H-20),
1.21 (1H, m), 1.38–1.63 (10H, m), 1.79 (1H, m),
1.95 (1H, dd, J1 2.4 Hz, J2 12.0 Hz), 1.97–2.07 (1H,
m), 2.11 (1H, m), 2.47 (1H, d, J 6.4 Hz), 2.49 (1H,
d, J 6.4 Hz), 3.41 (1H, dd, J1 4.0 Hz, J2 10.8 Hz, H-17),
3.49 (1H, dd, J1 4.0 Hz, J2 10.8 Hz, H-17). The
1H NMR data were in agreement with those in
literature[8], and the structure of 5 was identified as
abbeokutone.
3.6. Cloven-2β, 9α-diol (6)
White solid; 1H NMR (400 MHz, CD3OD) δ: 0.87
(3H, s, H-13), 0.91 (1H, d, J 12.5 Hz, H-12), 0.93 (3H,
s, H-15), 1.04 (3H, s, H-14), 1.58 (1H, d, J 12.5 Hz,
H-12), 1.09 (1H, m, H-11), 1.68 (1H, m, H-11), 1.66
(1H, m, H-10), 2.01 (1H, m, H-10), 3.24 (1H, br s,
H-9), 1.15 (1H, m, H-7), 1.52 (1H, m, H-7), 1.34
(1H, m, H-6), 1.37 (1H, m, H-6), 1.44 (1H, m, H-5),
1.53 (1H, dd, J1 10 Hz, J2 11.5 Hz, H-3), 1.73 (1H,
dd, J1 5.5 Hz, J2 11.5 Hz, H-3), 3.73 (1H, dd, J1 5.5 Hz,
J2 10.5 Hz, H-2). 13C NMR (100 MHz, CD3OD) δ:
45.4 (C-1), 81.4 (C-2), 48.1 (C-3), 37.7 (C-4), 52.0
(C-5), 21.7 (C-6), 34.5 (C-7), 35.8 (C-8), 76.0 (C-9),
26.8 (C-10), 27.9 (C-11), 36.7 (C-12), 25.8 (C-13),
31.8 (C-14), 29.1 (C-15). The 1H and 13C NMR data
were in agreement with those in literature[9], and the
structure of 6 was identified as cloven-2β,9α-diol.
3.7. 5-Hydroxy-1-(3,4-dihydroxyphenyl)-7-(4-
hydroxyphenyl)-3-heptanone (7)
Colorless oil; 1H NMR (400 MHz, CD3OD) δ: 1.67
(2H, m, H-6), 2.49–2.76 (8H, m, H-1,2,4,7), 4.01
(1H, m, H-5), 6.48 (1H, dd, J1 8.0 Hz, J2 2.0 Hz,
H-6′), 6.66–6.70 (4H, m, H-2,5,2,6), 6.99 (2H, d,
J 8.0 Hz, H-3,5). The 1H NMR data were in agree-
ment with those in literature, and the structure of 7
was identified as 5-hydroxy-1-(3,4-dihydroxyphenyl)-
7-(4-hydroxyphenyl)-3-heptanone[10].
3.8. 5-Hydroxy-7-(4-hydroxyphenyl)-1-phenyl-3-
heptanone (8)
Colorless oil; ESI-MS: m/z 321.2 [M+Na]+; 1H NMR
(400 MHz, CD3OD) δ: 1.67 (2H, m, H-1), 4.01 (1H,
m, H-5), 6.68–6.99 (4H, m, H-2, H-3, H-5, and
H-6), 7.12–7.26 (5H, m, H-2, H-3, H-4, H-5, and
H-6). 13C NMR (100 MHz, CD3OD) δ: 30.5 (C-1),
46.0 (C-2), 211.5 (C-3), 51.2 (C-4), 68.2 (C-5), 40.6
(C-6), 31.9 (C-7), 142.5 (C-1), 129.3 (C-2), 129.4
(C-3), 127.0 (C-4), 129.4 (C-5), 129.3 (C-6), 134.1
(C-1), 130.3 (C-2), 116.2 (C-3), 156.4 (C-4),
116.2 (C-5), 130.3 (C-6). The 1H and 13C NMR
data were in agreement with those in literature[11],
and the structure of 8 was identified as 5-hydroxy-7-
(4-hydroxyphenyl)-1-phenyl-3-heptanone.
3.9. 3,5,7-Trihydroxyflavone (9)
Yellow solid; 1H NMR (400 MHz, CD3OD) δ:
6.18 (1H, d, J 2.0 Hz, H-6), 6.39 (1H, d, J 2.0 Hz,
H-8), 7.41–7.51 (3H, m, H-2,4,6), 8.18 (2H, m,
H-3,5). Compound 9 was identified as 3,5,7-
trihydroxyflavone by comparison of the spectral
data with those reported in literature[12].
3.10. (4E)-7-(4-Hydroxy-3-methoxyphenyl)-1-
phenylhept-4-en-3-one (10)
Colorless oil; C20H22O3; ESI-MS: m/z 333.2 [M+Na]+;

G. Ni et al. / Journal of Chinese Pharmaceutical Sciences 21 (2012) 421–427 426
1H NMR (400 MHz, CD3OD) δ: 2.50 (2H, m, H-7),
2.68 (2H, m, H-6), 2.87 (4H, m, H-1 and H-2), 6.08
(1H, dt, J1 1.6 Hz, J2 16.0 Hz, H-4), 6.75 (1H, d,
J 1.6 Hz, H-2), 6.61 (1H, dd, J1 8.0 Hz, J2 1.6 Hz,
H-6), 6.70 (1H, d, J 8.0 Hz, H-5), 6.91 (1H, dt,
J1 6.8 Hz, J2 16.0 Hz, H-5), 7.12–7.26 (5H, m, H-2,
H-3, H-4, H-5, and H-6). 13C NMR (100 MHz,
CD3OD) δ: 30.7 (C-1), 42.3 (C-2), 202.3 (C-3), 131.6
(C-4), 148.9 (C-5), 35.0 (C-6), 35.7 (C-7), 142.5
(C-1), 129.3 (C-2), 129.4 (C-3), 127.0 (C-4), 129.4
(C-5), 129.3(C-6), 133.7 (C-1), 113.1 (C-2), 149.2
(C-3), 145.8 (C-4), 116.1 (C-5), 121.8 (C-6),
56.3 (3-OMe). The 1H and 13C NMR data were in
agreement with those in literature[13], and the
structure of 10 was identified as (4E)-7-(4-hydroxy-
3-methoxyphenyl)-1-phenylhept-4-en-3-one.
3.11. Yakuchinone B (11)
Colorless oil; ESI-MS: m/z 333.2 [M+Na]+; 1H NMR
(400 MHz, CD3OD) δ: 2.62–2.88 (8H, m), 6.10–6.23
(2H, m, H-1 and H-2), 6.60 (1H, dd, J1 2.0 Hz,
J2 8.0 Hz, H-6), 6.69 (1H, d, J 8.0 Hz, H-5), 6.76
(1H, d, J 2.0 Hz, H-2), 7.12–7.26 (5H, m, H-2,
H-3, H-4, H-5, and H-6). Compound 11 was
identified as yakuchinone B by comparison of the
spectral data with those reported in literature[14].
3.12. 4H-1-benzopyran-4-one (12)
Yellow solid; 1H NMR (400 MHz, CD3OD) δ: 2.76
(1H, dd, J1 3.2 Hz, J2 17.2 Hz, H-3), 3.08 (1H, dd,
J1 12.8 Hz, J2 17.2 Hz, H-3), 5.44 (1H, dd, J1 3.2 Hz,
J2 12.8 Hz, H-2), 5.90 (1H, d, J 2.4 Hz, H-6), 5.93
(1H, d, J 2.4 Hz, H-8), 7.34–7.50 (5H, m, H-2, H-3,
H-4, H-5, and H-6). The 1H NMR data were in
agreement with those in literature, and the structure
of 12 was identified as 4H-1-benzopyran-4-one[15].
References
[1] Wei, K.; Li, W.; Koike, K.; Liu, L.J.; Fu, X.W.; Lin,
L.B.; Chen, Y.J.; Nikaido, T. Chem. Pharm. Bull. 2004,
52, 776–779.
[2] Cheng, X.F.; Chen, Z.L.; Mu, M.Z. J. Asian Nat. Prod.
Res. 1999, 1, 163–168.
[3] Rivière, C.; Hong, V.N.T.; Hong, Q.T.; Chataigné, G.;
Hoai, N.N.; Dejaegher, B.; Tistaert, C.; Kim, T.N.T.;
Heyden, Y.V.; Van, M.C.; Leclercq, J.Q. Phytochem.
Rev. 2010, 9, 217–253.
[4] Ono, K.; Nakane, H.; Meng, Z.M.; Ose, Y.; Sakai, Y.;
Mizuno, M. Chem. Pharm. Bull. 1989, 37, 1810–1812.
[5] Tang, Z.J.; Song, C.Q.; Feng, S.C.; Yang, Y.P.; Xu, R.S.;
Zhong, Q.X.; Zhong, Y. Acta Chim. Sin. 1990, 48, 705–
708.
[6] Yang, Y.P.; Tang, Z.J.; Feng, S.C.; Xu, R.S.; Zhong,
Q.X.; Zhong, Y. Acta Chim. Sin. 1992, 50, 200–204.
[7] Yang, Y.P.; Tang, Z.J.; Xu, R.S.; Zhong, Q.X.; Zhong, Y.
Acta Chim. Sin. 1992, 50, 205–207.
[8] Mi, J.P.; Xu, R.S.; Yang, Y.P.; Yang, P.M. Acta Pharm.
Sin. 1993, 28, 105–109.
[9] Collado, I.G.; Hanson, J.R.; Sanchez, J.M. Tetrahedron.
1996, 52, 7961–7972.
[10] Li, S.B.; Liu, Y.G.; Zhu, M.Z. Chem. J. Chin. Univ. 2003,
24, 1414–1418.
[11] Kiuchi, F.; Shibuya, M.; Snakawa, U. Chem. Pharm.
Bull. 1982, 30, 2279–2282.
[12] Bankova, V.S.; Popov, S.S.; Marekov, N.L. J. Nat.
Prod. 1983, 46, 471–474.
[13] Tanaka, T.; Lchino, K.; Ito, K. Chem. Pharm. Bull.
1985, 33, 2602–2604.
[14] Itokawa, H.; Aiyama, R.; Ikuta, A. Phytochemistry.
1982, 21, 241–243.
[15] Ichino, K.; Tanaka, H.; Ito, K. Chem. Pharm. Bull. 1989,
37, 1426–1427.
锈毛野桐中的两个新二萜anomalusin A和anomalusin B
倪刚, 杨升平, 岳建民*
中国科学院上海药物研究所 国家新药研究重点实验室, 上海 201203

摘要: 从锈毛野桐中分离得到两个新的 ent-rosane 型二萜anomalusin A (1) 和 anomalusinB (2), 以及10个已知化合物。
化合物1和2的结构和相对构型通过波谱学方法确定, 它们的绝对构型通过CD谱确定。
关键词: 锈毛野桐; 二萜; 绝对构型

G. Ni et al. / Journal of Chinese Pharmaceutical Sciences 21 (2012) 421–427 427
Dr. Jianmin Yue received his B. Sc. degree in Chemistry in 1984 from Lanzhou University, where
he also completed his Ph. D. degree in Organic Chemistry in 1990. He was a postdoctoral (1991–1993)
in the Department of Phytochemistry, Kunming Institute of Botany, Chinese Academy of Sciences
(CAS), and in the School of Chemistry, University of Bristol as a postdoctoral (1993–1994) UK. Then
he returned to Kunming Institute of Botany and worked as an Associate Professor (1994–1996). He
joined the staff of the Joint Laboratory of Unilever Research and Shanghai Institute of Organic Chemistry,
CAS, as a Senior Research Scientist (1996–1999) on natural products chemistry. He then moved to
Shanghai Institute of Materia Medica (SIMM), CAS, taking a position of Professor in medicinal chemistry where he remains up
to now. Currently, he serves as the head of Department of Natural Products of SIMM, and deputy director of Chinese National
Compound Library. During his research career, he has published over 200 scientific papers. His group is actively involved in the
isolation, structure determination, and synthetic optimization of natural products, and currently focused on natural products with
activity against infectious diseases, cancer and neurodegenerative disorders.
岳建民博士, 1984年毕业于兰州大学化学系, 获学士学位, 并于1990年在该校获理学博士学位; 1991–1993年, 中国
科学院昆明植物研究所从事博士后研究; 1993–1994年, 英国 Bristol大学化学学院从事博士后研究; 1994–1996年任中国科
学院昆明植物研究所副研究员; 1996–1999年, 任中国科学院上海有机化学研究所-联合利华联合实验室资深研究人员;
1999年至今, 任中国科学院上海药物研究所研究员, 现任上海药物研究所天然药物研究室主任, 国家化合物库副主任。
已发表研究论文200多篇。研究方向: 天然活性化合物的发现与结构优化, 以及抗感染、抗肿瘤和治疗神经退行性疾病药
物先导结构的发现与研究。